高危TP53突变急性髓系白血病首次缓解期成人患者接受单倍体、同胞全合或无关供者造血细胞移植的结局相似:全球委员会与欧洲血液和骨髓移植学会急性白血病工作组比较研究
该回顾性研究分析了2010至2021年间首次完全缓解期接受异基因造血细胞移植的451例TP53突变急性髓系白血病成人患者,比较单倍体(86例)、同胞全合(117例)与10/10全合无关供者(248例)的移植结局。多因素分析显示三组在180天II-IV级及III-IV级急性移植物抗宿主病、2年慢性移植物抗宿主病、2年总生存、无白血病生存、复发率、非复发死亡及无移植物抗宿主病无复发生存方面均无显著差异。
要点
- 三组180天II-IV级急性移植物抗宿主病发生率分别为单倍体30.9%、同胞全合23.6%、无关供者28.3%。
- 单倍体组2年总生存46.7%,同胞全合组33.9%(p=0.799),无关供者组36.9%(p=0.892)。
- 多因素分析显示单倍体、同胞全合与10/10全合无关供者移植结局相似。
核心结论
- TP53突变急性髓系白血病患者接受单倍体供者移植的结局与同胞全合或10/10全合无关供者移植相当。
研究设计与样本
- 回顾性分析2010至2021年间首次完全缓解期接受异基因造血细胞移植的成人TP53突变急性髓系白血病患者,共451例,其中单倍体86例、同胞全合117例、10/10全合无关供者248例。
主要发现
- 单倍体组、同胞全合组与无关供者组180天II-IV级急性移植物抗宿主病发生率分别为30.9%、23.6%、28.3%。
- 单倍体组、同胞全合组与无关供者组180天III-IV级急性移植物抗宿主病发生率分别为13.6%、10.1%、9.1%。
- 单倍体组、同胞全合组与无关供者组2年慢性移植物抗宿主病发生率分别为28.9%、30.9%、25.6%,广泛型慢性移植物抗宿主病分别为10.9%、16.1%、13.3%。
- 同胞全合组与单倍体组相比,2年总生存33.9%对46.7%(p=0.799),无白血病生存30.5%对37.4%(p=0.956),复发率54.2%对40.8%(p=0.497),非复发死亡15.3%对21.7%(p=0.368),无移植物抗宿主病无复发生存21.8%对25.7%(p=0.957)。
- 无关供者组与单倍体组相比,2年总生存36.9%对46.7%(p=0.892),无白血病生存31%对37.4%(p=0.904),复发率50.8%对40.8%(p=0.521),非复发死亡18.2%对21.7%(p=0.368),无移植物抗宿主病无复发生存21.9%对25.7%(p=0.383)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the dismal prognosis for patients with TP53-mutated acute myeloid leukemia (AML), the optimal donor for those undergoing allogeneic hematopoietic cell transplantation (allo-HCT) remains unclear. We retrospectively analyzed adult patients with TP53-mutated AML who underwent first allo-HCT in CR1 between 2010 and 2021. Outcomes were compared among using a haploidentical donor (Haplo), a matched sibling donor (MSD), and a 10/10 matched unrelated donor (MUD). The analysis comprised 451 patients, including 86 Haplo, 117 MSD, and 248 MUD. Patients in the three groups were transplanted during a similar period. Haplo, MSD, and MUD groups experienced similar incidences of Day 180 Grades II-IV aGVHD (30.9% vs. 23.6% vs. 28.3%), Grades III-IV aGVHD (13.6% vs. 10.1% vs. 9.1%), 2-year cGVHD (28.9.% vs. 30.9% vs. 25.6%) and extensive cGVHD (10.9% vs. 16.1% vs. 13.3%). By multivariate analysis, the outcomes were similar in the three groups. The MSD group was associated with a similar 2-year overall survival (OS: 33.9%; p = 0.799), leukemia-free survival (LFS: 30.5%; p = 0.956), relapse incidence (RI: 54.2%; p = 0.497), non-relapse mortality (NRM: 15.3%; p = 0.368), and GVHD-free, relapse-free survival (GRFS: 21.8%, p = 0.957) when compared with the Haplo group (2-year OS: 46.7%, LFS: 37.4%, RI: 40.8%, NRM: 21.7%, GRFS: 25.7%). The MUD group also experienced a similar 2-year OS (36.9%; p = 0.892), LFS (31%; p = 0.904), RI (50.8%; p = 0.521), NRM (18.2%; p = 0.368) and GRFS (21.9%; p = 0.383) when compared with the Haplo group. In conclusion, outcomes of patients with TP53-mutated AML undergoing allo-HCT from a haploidentical donor were comparable to those from an MSD or 10/10 MUD HCT.
引用
- Ru Y, Chen J, Ferhat AT, et al. Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2025. PMID: 40927841. doi:10.1002/ajh.70069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。